SCHEMBL2196167

SCHEMBL2196167

O=C(OC=Cc1ccccc1)OC1CC2CCC1C2

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.48
HPGD P15428 2/20 0.48
ATM Q13315 1/20 0.46
CYP19A1 P11511 1/20 0.42
LMNA P02545 1/20 0.38
MC4R P32245 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
SLC6A3 Q01959 1/20 0.38
CTSV O60911 1/20 0.37
CTSL P07711 1/20 0.37
CTSS P25774 1/20 0.37
CTSK P43235 1/20 0.37
MAPK1 P28482 1/20 0.36
PDE4A P27815 2/20 0.35
PDE4B Q07343 2/20 0.35
PDE4C Q08493 2/20 0.35
PDE4D Q08499 2/20 0.35
GRM1 Q13255 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14619688 0.81 ATM (0.62) SMN1; SMN2HPGDATMCYP19A1LMNA
SCHEMBL1397151 0.81 ATM (0.62) SMN1; SMN2HPGDATMCYP19A1LMNA
SCHEMBL1702936 0.81 HPGD (0.48) SMN1; SMN2HPGDATMCYP19A1LMNA
SCHEMBL1397172 0.79 HPGD (0.46) SMN1; SMN2HPGDATMCYP19A1L3MBTL1
SCHEMBL1397133 0.73 FABP7 (0.43) SMN1; SMN2LMNAMAPK1RAB9A
SCHEMBL14619845 0.73 CHRM2 (0.50) ATMCYP19A1SLC6A3GRM1
SCHEMBL377478 0.73 HDAC1 (0.52) SMN1; SMN2LMNAMAPK1RAB9A
SCHEMBL3073477 0.73 ATM (0.59) SMN1; SMN2ATMCYP19A1LMNAMC4R
SCHEMBL7025388 0.72 ATM (0.53) ATMCYP19A1PDE4APDE4BPDE4C
SCHEMBL8860983 0.70 CYP19A1 (0.75) SMN1; SMN2HPGDATMCYP19A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107207456-B Latent acids and their use 巴斯夫欧洲公司 2021-05-04 CN disclosed
EP-3253735-B1 LATENT ACIDS AND THEIR USE BASF SE (DE) 2021-03-31 EP disclosed
US-20180009775-A1 LATENT ACIDS AND THEIR USE BASF SE (DE) 2018-01-11 US disclosed
WO-2016124493-A1 LATENT ACIDS AND THEIR USE BASF SE (DE) 2016-08-11 WO disclosed
EP-2197840-B1 SULPHONIUM SALT INITIATORS BASF SE (DE) 2013-11-06 EP disclosed
EP-2197869-B1 SULPHONIUM SALT INITIATORS BASF SE (DE) 2013-04-24 EP disclosed
EP-1472576-B1 SULFONATE DERIVATIVES AND THE USE THEROF AS LATENT ACIDS BASF SE (DE) 2013-04-24 EP disclosed
EP-2349993-B1 SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS BASF SE (DE) 2012-12-12 EP disclosed
EP-2349993-A1 SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS BASF SE (DE) 2011-08-03 EP disclosed
US-20110171569-A1 SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS BASF SE (DE) 2011-07-14 US disclosed
WO-2010046240-A1 SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS BASF SE (DE) 2010-04-29 WO disclosed
EP-1320785-B1 OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS BASF SE (DE) 2010-02-17 EP disclosed
EP-2030081-A2 OXIME SULFONATES AND THE USE THEROF AS LATENT ACIDS Ciba Holding Inc. (CH) 2009-03-04 EP disclosed
WO-2007147782-A2 OXIME SULFONATES AND THE USE THEROF AS LATENT ACIDS CIBA HOLDING INC. (CH) 2007-12-27 WO disclosed
US-6261738-B1 LATENT CURING CATALYSTS FOR PHOTORESISTS SUCH AS 2,2,2-TRIFLUORO-1-PHENYL-ETHANONE OXIME-O-METHYL SULFONATE CIBA SPECIALTY CHEMICALS CORPORATION 2001-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180009775-A1 LATENT ACIDS AND THEIR USE LTA, C1S, C9 SMN1; SMN2 4885/4885HPGD 945/4885ATM 3063/4885
US-20110171569-A1 SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS NR2E3, HCAR3, HRH4 SMN1; SMN2 3099/4885HPGD 3730/4885ATM 1725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.